Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of <i>FLT3</i>-Mutant Acute Myeloid Leukemia
Amir T. Fathi(University of Southern California), Yi‐Bin Chen(Massachusetts General Hospital), Darrel R. Borger(Harvard University), Hossein Sadrzadeh(Boston University), Lindsay A. Bernardo(Harvard University), Daniela Kroshinsky(Massachusetts General Hospital), Tyler Durazzo(Harvard University), William M. Lin(Broad Institute), Steven L. McAfee(Harvard University), Adriano Piris(Brigham and Women's Hospital)
Cited by 3
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996